PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 104 filers reported holding PHATHOM PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,922,971 | -8.8% | 667,596 | +26.0% | 0.00% | – |
Q2 2023 | $7,587,352 | +129.1% | 529,843 | +14.3% | 0.00% | – |
Q1 2023 | $3,311,125 | -67.3% | 463,743 | -48.6% | 0.00% | – |
Q4 2022 | $10,128,272 | +105.2% | 902,698 | +102.6% | 0.00% | – |
Q3 2022 | $4,936,000 | +43.0% | 445,495 | +9.0% | 0.00% | – |
Q2 2022 | $3,451,000 | -30.5% | 408,882 | +12.0% | 0.00% | – |
Q1 2022 | $4,968,000 | -26.1% | 365,044 | +6.8% | 0.00% | – |
Q4 2021 | $6,726,000 | -40.9% | 341,940 | -3.6% | 0.00% | -100.0% |
Q3 2021 | $11,388,000 | -1.1% | 354,764 | +4.2% | 0.00% | 0.0% |
Q2 2021 | $11,519,000 | +41.2% | 340,303 | +56.7% | 0.00% | – |
Q1 2021 | $8,158,000 | +17.5% | 217,198 | +3.9% | 0.00% | – |
Q4 2020 | $6,945,000 | -11.6% | 209,050 | -2.5% | 0.00% | -100.0% |
Q3 2020 | $7,859,000 | +12.2% | 214,307 | +0.7% | 0.00% | 0.0% |
Q2 2020 | $7,003,000 | +44.8% | 212,807 | +13.6% | 0.00% | – |
Q1 2020 | $4,836,000 | +24.0% | 187,308 | +49.6% | 0.00% | – |
Q4 2019 | $3,900,000 | – | 125,243 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $40,675,000 | 10.18% |
FRAZIER MANAGEMENT LLC | 5,827,415 | $114,625,000 | 8.82% |
Abingworth LLP | 1,203,135 | $23,606,000 | 5.72% |
RA Capital Management | 3,115,008 | $61,272,000 | 1.08% |
Avidity Partners Management LP | 1,896,000 | $37,294,000 | 0.79% |
StepStone Group LP | 422,085 | $8,302,000 | 0.47% |
Summit Rock Advisors, LP | 34,100 | $671,000 | 0.40% |
Parkman Healthcare Partners LLC | 77,481 | $1,524,000 | 0.34% |
Rhenman & Partners Asset Management AB | 186,210 | $3,624,000 | 0.24% |
Ikarian Capital, LLC | 74,560 | $1,467,000 | 0.22% |